INS and cardiovascular disorder: Sotagliflozin, when used in combination with insulin therapy, resulted in significant reductions in cardiovascular disease (CVD) risk (−6.38%; 95% CI: −7.63 to −5.1; P < 0.05) and end-stage kidney disease (ESKD) risk (−5.0%; 95% CI: −7.62 to −2.3; P < 0.05).